[BIOSTAR PHARMACEUTICALS, INC. BEGINS CONSTRUCTION OF RAW MATERIAL PROCESSING FACILITY OF THE HERBAL PLANTATION BASE Press Release Source: Biostar Pharmaceuticals, Inc. On Monday June 29, 2009, 8:00 am EDT BSPM News ; XIANYANG, China, June 29 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: Biostar has finished the engineering design and commenced construction for its new raw material processing facility]
[BIOSTAR PHARMACEUTICALS, INC. BEGINS CONSTRUCTION OF RAW MATERIAL PROCESSING FACILITY OF THE HERBAL PLANTATION BASE Press Release Source: Biostar Pharmaceuticals, Inc. On Monday June 29, 2009, 8:00 am EDT BSPM News ; XIANYANG, China, June 29 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: Biostar has finished the engineering design and commenced construction for its new raw material processing facility]
[Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program NEW YORK and Xianyang, China, The Company’s flagship product is the Xin Ao Xing Oleanolic Acid Capsule, the only SFDA approved OTC drug from the local level to the state level which treats chronic hepatitis B, a condition which affects 10% of the Chinese population. In addition, the]
[Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program NEW YORK and Xianyang, China, The Company’s flagship product is the Xin Ao Xing Oleanolic Acid Capsule, the only SFDA approved OTC drug from the local level to the state level which treats chronic hepatitis B, a condition which affects 10% of the Chinese population. In addition, the]
[Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 Investments in Infrastructure Expected To Positively Effect Performance This Year New York, New York – May 27, 2009 – Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) (OTCBB: BSPM) today reported financial results for the three months ended March 31, 2009. The Company reported revenue of $7,447,664]
[Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 Investments in Infrastructure Expected To Positively Effect Performance This Year New York, New York – May 27, 2009 – Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) (OTCBB: BSPM) today reported financial results for the three months ended March 31, 2009. The Company reported revenue of $7,447,664]
[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2009 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-5101287 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 4 v149063_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer EX-32.2 5 v149063_ex32-2.htm]
[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2009 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-5101287 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 4 v149063_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer EX-32.2 5 v149063_ex32-2.htm]
[Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings For 2008 Sales Up 118% to $33 Million, Net Income Increased 69% to $6.7 Million Over Prior Year New York, New York – April 7, 2009 – Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) (OTCBB: BSPM) today reported financial results for the 12 months ended December 31, 2008. Highlights for Year Ended]
[Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings For 2008 Sales Up 118% to $33 Million, Net Income Increased 69% to $6.7 Million Over Prior Year New York, New York – April 7, 2009 – Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) (OTCBB: BSPM) today reported financial results for the 12 months ended December 31, 2008. Highlights for Year Ended]
